Sandoz Group AG (SWX:SDZ)
37.89
+0.55 (1.47%)
Mar 28, 2025, 3:02 PM CET
Sandoz Group AG Revenue
In the year 2024, Sandoz Group AG had annual revenue of $10.38B USD with 4.06% growth. Sandoz Group AG had revenue of $5.32B in the half year ending December 31, 2024, with 14.92% growth.
Revenue
$10.38B
Revenue Growth
+4.06%
P/S Ratio
1.71
Revenue / Employee
$470.95K
Employees
22,049
Market Cap
16.08B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSandoz Group AG News
- 10 days ago - Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE - Benzinga
- 22 days ago - Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ... - GuruFocus
- 23 days ago - US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says - Financial Post
- 23 days ago - Health Care Roundup: Market Talk - The Wall Street Journal
- 23 days ago - Sandoz Group AG Non-GAAP EPS of $2.71, revenue of $10.36B; initiates FY25 outlook - Seeking Alpha
- 4 weeks ago - NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects - Benzinga
- 4 weeks ago - Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications - Seeking Alpha
- 4 weeks ago - MS patients suffer side-effects after NHS England switches to cheaper drug - The Guardian